Mechanistic Target of Rapamycin (mTOR) is a serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase family that functions as the master integrator of anabolic signaling in eukaryotic cells, coupling nutrient availability, energy status, growth factor signaling, and stress signals to the decision of whether a cell should grow, proliferate, and synthesise macromolecules or, conversely, conserve resources through catabolic recycling programmes such as autophagy. Named after the bacterial macrolide rapamycin (isolated from Streptomyces hygroscopicus on Easter Island β "Rapa Nui" β in the 1970s), mTOR sits at a regulatory node of extraordinary importance: when nutrients and growth signals are abundant, mTOR activation drives protein synthesis, lipid synthesis, nucleotide synthesis, and mitochondrial biogenesis while simultaneously suppressing autophagy; when nutrients are scarce, energy is depleted, or cellular stress is present, mTOR inhibition lifts the brake on autophagy, activates lysosomal biogenesis, promotes metabolic flexibility, and shifts the cell from growth mode to survival mode. This binary logic β grow or recycle β is the molecular foundation of the cPNI principle that health requires periodic cycling between anabolic and catabolic states.
In clinical psychoneuroimmunology, mTOR occupies a central position because its dysregulation connects the defining features of modern chronic disease: constant food availability (especially high protein and high glycaemic loads) combined with physical inactivity creates a state of chronic mTOR activation that accelerates aging (senescence), promotes Cancer growth, impairs autophagy (preventing clearance of damaged organelles, misfolded proteins, and intracellular pathogens), maintains chronic low-grade inflammation (because autophagic clearance of inflammasomes and damaged mitochondria is suppressed), and drives insulin resistance through S6K1-mediated IRS-1 degradation. The evolutionary mismatch is stark: our ancestors experienced obligatory cycling between fed and fasted states, between physical exertion and rest, between mTOR activation and mTOR inhibition. Modern environments β with 24-hour food availability, frequent high-protein meals, and sedentary behaviour β lock mTOR in a chronically active state that the human genome never evolved to handle.
Understanding mTOR is therefore not merely an exercise in molecular biology β it is the mechanistic foundation for some of the most powerful lifestyle interventions in cPNI practice: Intermittent fasting (which creates windows of mTOR inhibition and autophagy activation), protein cycling and meal timing (which allow strategic mTOR activation for Muscle hypertrophy followed by mTOR inhibition for autophagy), and physical activity periodisation (where exercise initially activates AMPK to inhibit mTOR, then recovery feeding activates mTOR for muscle repair and growth). The goal is not permanent mTOR suppression β which would impair immune function, wound healing, and muscle maintenance β but healthy oscillation between activation and inhibition, mimicking the ancestral metabolic environment.
mTOR exists in two structurally and functionally distinct multiprotein complexes that share the mTOR kinase catalytic subunit but differ in their accessory proteins, upstream regulators, downstream targets, and sensitivity to rapamycin:
mTORC1 (mTOR Complex 1) consists of mTOR kinase, Raptor (Regulatory-Associated Protein of mTOR), mLST8 (also called GbetaL), PRAS40 (Proline-Rich Akt Substrate of 40 kDa), and DEPTOR (DEP domain-containing mTOR-interacting protein). Raptor is the defining scaffolding component that recruits mTORC1 substrates (S6K1, 4E-BP1) by recognising their TOS (TOR signaling) motifs, and it is through Raptor that the FKBP12-rapamycin complex inhibits mTORC1 β rapamycin binds FKBP12, which then directly binds Raptor, allosterically disrupting substrate access to the mTOR kinase domain. PRAS40 and DEPTOR are inhibitory components: under low-nutrient conditions they suppress mTORC1 activity, and their phosphorylation-dependent displacement by Akt signaling is part of the activation mechanism. mTORC1 is the nutrient-sensitive, rapamycin-sensitive complex and the primary regulator of protein synthesis and autophagy.
mTORC2 (mTOR Complex 2) consists of mTOR kinase, Rictor (Rapamycin-Insensitive Companion of mTOR), mSIN1 (Mammalian Stress-activated protein kinase Interacting protein 1), mLST8, and DEPTOR. The replacement of Raptor with Rictor confers insensitivity to acute rapamycin treatment (though prolonged rapamycin exposure can eventually disrupt mTORC2 assembly in some cell types). mTORC2 responds primarily to growth factors (via PI3K signaling) rather than to amino acids directly, and its best-characterised function is the phosphorylation of Akt at serine 473 β the "full activation" phosphorylation that is required for Akt to achieve maximum catalytic activity. mTORC2 also phosphorylates serum and glucocorticoid-regulated kinase 1 (SGK1, important for sodium transport and blood pressure regulation) and protein kinase C (PKC, important for cytoskeletal organisation). Through Akt Ser473 phosphorylation, mTORC2 sits upstream of mTORC1 in a feed-forward arrangement: growth factor β PI3K β mTORC2 β Akt (fully active) β TSC2 inactivation β mTORC1 activation.
A defining feature of mTORC1 regulation is that it functions as a coincidence detector β requiring the simultaneous presence of both amino acids AND growth factor/insulin signaling for full activation. Neither input alone is sufficient. This two-signal requirement makes biological sense: the cell should only commit to energy-expensive anabolic programmes (protein synthesis, lipid synthesis) when both the building blocks (amino acids) and the hormonal signals confirming systemic nutrient sufficiency (insulin, growth factors) are present.
Amino acid sensing occurs through an elegant machinery centred on the lysosomal surface. Leucine, the most potent amino acid activator of mTORC1, is sensed by Sestrin2 β in the absence of leucine, Sestrin2 binds to and inhibits the GATOR2 complex; when leucine binds directly to Sestrin2, it releases GATOR2, which then inhibits GATOR1 (a GAP for the Rag GTPases). With GATOR1 suppressed, the Rag GTPases (RagA/B-RagC/D heterodimers) adopt their active conformation and recruit mTORC1 from the cytoplasm to the lysosomal surface via Raptor. Arginine is sensed through a parallel pathway involving CASTOR1 (Cellular Arginine Sensor for mTORC1), which similarly regulates GATOR2. Other amino acids β including methionine (via SAMTOR, which senses S-adenosylmethionine levels) and glutamine β have their own sensing mechanisms converging on the Rag-Ragulator complex. The lysosomal localisation of mTORC1 is essential because that is where its key activator, the small GTPase Rheb (Ras Homolog Enriched in Brain), resides.
Growth factor/insulin signaling converges on mTORC1 through the PI3K-Akt-TSC pathway. Insulin or IGF-1 binds its receptor tyrosine kinase, activating PI3K, which generates PIP3, which recruits and activates Akt (protein kinase B). Akt phosphorylates and inactivates the TSC1/TSC2 (tuberous sclerosis complex) heterodimer, which functions as a GAP (GTPase-activating protein) for Rheb. When TSC1/2 is active (in the absence of growth factor signaling), it keeps Rheb in the inactive GDP-bound state; when TSC1/2 is inactivated by Akt phosphorylation, Rheb switches to the active GTP-bound state and directly activates mTORC1 on the lysosomal surface. Thus, both inputs converge at the lysosome: amino acids recruit mTORC1 to the lysosome via the Rag GTPases, and insulin/growth factors activate Rheb at the lysosome via TSC1/2 inactivation β mTORC1 must be both recruited to and activated at the lysosome for signaling to proceed.
Energy status provides a third layer of regulation through AMPK (AMP-activated protein kinase). When cellular energy is depleted (high AMP:ATP ratio), AMPK is activated and directly phosphorylates TSC2, enhancing its GAP activity and suppressing Rheb β thereby inhibiting mTORC1 even in the presence of amino acids and growth factors. AMPK also phosphorylates Raptor directly, further suppressing mTORC1. This creates a hierarchical override: energy depletion trumps nutrient and growth factor signals, ensuring that cells do not attempt energy-expensive anabolic processes when ATP is limiting.
When fully activated, mTORC1 phosphorylates multiple downstream substrates that collectively drive the anabolic programme:
S6K1 (Ribosomal Protein S6 Kinase 1, also called p70S6K): Phosphorylation at Thr389 by mTORC1 activates S6K1, which then phosphorylates ribosomal protein S6 and eIF4B, promoting ribosome biogenesis and translational efficiency. S6K1 also phosphorylates and promotes the degradation of PDCD4, a translational repressor. Critically for metabolic health, S6K1 also phosphorylates insulin receptor substrate-1 (IRS-1) on inhibitory serine residues, creating a negative feedback loop: chronic mTOR-S6K1 activation degrades the insulin signaling scaffold, producing insulin resistance. This S6K1-mediated IRS-1 degradation is a primary molecular mechanism by which chronic overfeeding and constitutive mTOR activation drive the insulin resistance of metabolic syndrome and type 2 diabetes.
4E-BP1 (eIF4E-Binding Protein 1): In its unphosphorylated state, 4E-BP1 sequesters the translation initiation factor eIF4E, preventing cap-dependent translation of mRNAs. mTORC1 phosphorylation of 4E-BP1 releases eIF4E, allowing it to assemble the eIF4F initiation complex and begin cap-dependent translation. Cap-dependent translation preferentially promotes the translation of mRNAs with complex 5' untranslated regions, which encode many growth-promoting and pro-survival proteins.
SREBP (Sterol Regulatory Element-Binding Proteins): mTORC1 promotes the processing and nuclear translocation of SREBP1 and SREBP2, master transcription factors for fatty acid and cholesterol synthesis genes, respectively. This links mTOR activation to lipid biosynthesis β explaining why chronic mTOR activation in the context of overnutrition drives hepatic lipogenesis, contributing to Fatty Liver Disease and dyslipidaemia.
ULK1 inhibition (Unc-51 Like Autophagy Activating Kinase 1): mTORC1 directly phosphorylates ULK1 at Ser757, preventing ULK1 from being activated by AMPK and thereby suppressing the initiation of autophagy. This is the central mechanism by which mTOR activation blocks autophagy: as long as mTORC1 is active, ULK1 cannot initiate autophagosome formation. When mTORC1 is inhibited (by fasting, exercise-induced AMPK activation, or rapamycin), ULK1 is dephosphorylated and can be activated by AMPK to initiate autophagy.
TFEB inhibition (Transcription Factor EB): mTORC1 phosphorylates TFEB on the lysosomal surface, retaining it in the cytoplasm and preventing its nuclear translocation. When mTORC1 is inhibited, TFEB translocates to the nucleus and drives transcription of genes involved in lysosomal biogenesis, autophagy, and lysosomal exocytosis β the "CLEAR" (Coordinated Lysosomal Expression and Regulation) network. This means mTOR inhibition not only initiates autophagy (via ULK1 derepression) but also builds the lysosomal machinery needed to complete autophagy β an elegant two-pronged mechanism.
mTORC2 is less well characterised but plays essential roles in cellular physiology. Its phosphorylation of Akt at Ser473 (the "hydrophobic motif") is required for full Akt activation, which then drives multiple downstream pathways including FOXO transcription factor inhibition (promoting cell survival), GSK-3beta inhibition (promoting glycogen synthesis), and TSC2 inactivation (activating mTORC1 β the feed-forward loop). mTORC2 also regulates cytoskeletal organisation through PKC-alpha phosphorylation, influencing cell migration, morphology, and potentially metastatic potential in cancer. Through SGK1 phosphorylation, mTORC2 influences ion channel function and sodium homeostasis. Metabolically, mTORC2 promotes glucose uptake and lipogenesis through Akt-dependent mechanisms and is required for the metabolic reprogramming that accompanies T-cell activation, connecting it to Immunometabolism.
AMPK (5'-AMP-activated protein kinase) is the cellular energy sensor that functions as the physiological counterbalance to mTOR. When the AMP:ATP ratio rises β indicating energy depletion from physical activity, Intermittent fasting, caloric restriction, or cellular stress β AMPK is activated by the upstream kinase LKB1 (and by CaMKKbeta in response to calcium signals). Activated AMPK inhibits mTORC1 through two complementary mechanisms: direct phosphorylation of TSC2 (enhancing its GAP activity against Rheb) and direct phosphorylation of Raptor (disrupting mTORC1 complex integrity). Simultaneously, AMPK activates catabolic pathways: fatty acid oxidation (Beta-oxidation) through ACC phosphorylation, glucose uptake through GLUT4 translocation, mitochondrial biogenesis through PGC-1alpha activation, and autophagy through direct ULK1 phosphorylation at Ser317 and Ser777 (activating sites, distinct from the mTORC1-mediated inhibitory Ser757 site).
The AMPK-mTOR axis represents a fundamental metabolic switch: AMPK ON / mTOR OFF = catabolism, autophagy, metabolic flexibility, stress resistance; AMPK OFF / mTOR ON = anabolism, protein synthesis, growth, autophagy suppression. Pharmacological AMPK activators include metformin (indirect, via Complex I inhibition and AMP elevation), berberine (similar mechanism), AICAR (direct AMP analogue), and salicylate (direct AMPK binding). Natural AMPK activation occurs through exercise, fasting, caloric restriction, cold exposure, and polyphenols such as resveratrol and EGCG. The convergence of so many cPNI lifestyle interventions on AMPK activation and consequent mTOR inhibition highlights why this pathway axis is considered the molecular target of intermittent living strategies.
The key cPNI insight regarding mTOR is that the problem is not mTOR activation per se β which is essential for Muscle hypertrophy, immune cell proliferation, wound healing, and tissue maintenance β but rather the absence of mTOR inhibition periods. In ancestral environments, the mTOR-AMPK axis oscillated naturally: physical exertion (hunting, gathering, migration) activated AMPK and suppressed mTOR; subsequent feeding activated mTOR to drive tissue repair and protein synthesis; overnight fasting again suppressed mTOR and activated autophagy. This oscillation β what Leo Pruimboom conceptualises as part of Intermittent Living β is the healthy pattern.
The modern problem is constitutive mTOR activation: frequent meals (3 meals plus snacks, consuming food from early morning to late evening with a feeding window of 14-16 hours), high protein intake at every meal (providing continuous leucine to drive mTORC1 via Sestrin2/GATOR), combined with physical inactivity (no AMPK activation to counter-regulate mTOR). The result is chronically suppressed autophagy, accelerated cellular aging, accumulated damaged mitochondria and misfolded proteins, sustained S6K1-mediated insulin resistance, and impaired Metabolic flexibility.
The cPNI prescription for healthy mTOR cycling includes: (1) Time-restricted eating β a feeding window of 8-10 hours creates a 14-16 hour fasting window during which mTOR is suppressed and autophagy is activated (mTOR downregulation typically becomes significant after 12-16 hours of fasting, depending on glycogen status and metabolic flexibility); (2) Protein timing β concentrating protein intake in the post-exercise feeding window and in 1-2 meals rather than distributing it across all meals and snacks provides strategic mTOR activation for muscle protein synthesis followed by periods of mTOR suppression; (3) Leucine threshold β approximately 2-3g of Leucine per meal is needed to meaningfully activate mTORC1 for muscle protein synthesis, which requires about 25-30g of high-quality protein; (4) Exercise periodisation β resistance training or high-intensity exercise first activates AMPK (during the exercise itself), then the post-exercise meal with protein activates mTOR for the recovery and adaptation phase. This exercise β fast β feed β rest cycle recapitulates the ancestral metabolic oscillation at the molecular level.
Rapamycin (sirolimus) is a macrolide compound that forms a complex with the intracellular protein FKBP12, which then binds to the FRB (FKBP12-rapamycin binding) domain of mTOR, allosterically inhibiting mTORC1 (but not acutely mTORC2). Rapamycin is FDA-approved as an immunosuppressant (used in organ transplantation) and as an anti-cancer agent (mTOR-driven tumour proliferation), but it has gained enormous attention in geroscience because it is the most robust pharmacological intervention for extending lifespan in model organisms: rapamycin extends life expectancy in yeast, nematodes (C. elegans), fruit flies (Drosophila), and mice (by 9-26% depending on study, strain, and dosing protocol), even when started late in life. In mice, rapamycin treatment reduces age-related pathology including cancer, cardiovascular disease, cognitive decline, and immune senescence. These effects are attributed to restored autophagy (clearing senescent cells and damaged organelles), reduced senescence-associated secretory phenotype (SASP), improved stem cell function, and decreased inflammatory signaling.
However, chronic rapamycin use carries significant side effects: immunosuppression (particularly impaired T-cell function), hyperlipidaemia, impaired glucose tolerance (paradoxically, through mTORC2 disruption with prolonged exposure), delayed wound healing, and mouth ulcers. The cPNI perspective is that lifestyle-based mTOR modulation β through Intermittent fasting, exercise periodisation, protein cycling, and stress exposures (Intermittent Living) β achieves many of the same molecular endpoints as rapamycin (AMPK activation, mTOR suppression, autophagy induction) without the side effects of chronic pharmacological suppression, and with the added benefit of preserving the healthy oscillation between mTOR activation (needed for tissue repair and immune function) and mTOR inhibition (needed for autophagy and longevity).
mTOR is hyperactivated in the majority of human cancers through various mechanisms: activating mutations in PI3K or Akt, loss-of-function mutations in TSC1/2 or PTEN (the phosphatase that degrades PIP3, opposing PI3K), or constitutive growth factor receptor activation. Hyperactive mTOR drives the Warburg metabolic phenotype in cancer (aerobic glycolysis + anabolic synthesis), promotes cancer cell proliferation, suppresses autophagy (preventing quality control), and β through S6K1 and 4E-BP1 β selectively enhances translation of oncogenic mRNAs. mTOR inhibitors (rapamycin analogues/rapalogs: everolimus, temsirolimus) are used in renal cell carcinoma, breast cancer, neuroendocrine tumours, and tuberous sclerosis complex-associated tumours. From a cPNI prevention perspective, lifestyle strategies that prevent chronic mTOR activation β maintaining healthy body composition, regular physical activity, Intermittent fasting, and moderate protein intake β represent a molecular cancer prevention strategy.
The mTORC1-S6K1-IRS-1 negative feedback loop is a primary driver of nutrient-induced insulin resistance. Chronic mTOR activation by high-protein, high-calorie diets drives sustained S6K1 activity, which phosphorylates IRS-1 on inhibitory serine residues (Ser307, Ser636/639), promoting IRS-1 ubiquitination and proteasomal degradation. The result is desensitisation of insulin signaling despite adequate or elevated insulin levels β the molecular hallmark of type 2 diabetes and metabolic syndrome. S6K1 knockout mice are protected from diet-induced obesity and insulin resistance, directly demonstrating this pathway's significance. This mechanism explains why interventions that periodically inhibit mTOR β fasting, exercise, caloric restriction β improve insulin sensitivity independent of weight loss.
mTOR plays a central role in immune cell activation and differentiation, and its dysregulation contributes to the age-related decline in immune function (immunosenescence). Activated T cells undergo metabolic reprogramming that requires mTOR β switching from oxidative phosphorylation to aerobic glycolysis and anabolic synthesis to support rapid clonal expansion. mTORC1 drives CD4+ T helper cell differentiation toward Th1, Th2, and Th17 effector phenotypes, while mTOR inhibition promotes regulatory T cell (Treg) differentiation. In aging, chronic mTOR activation in immune cells contributes to inflammaging, impaired vaccine responses, and reduced anti-pathogen immunity. Paradoxically, the mTOR inhibitor everolimus has been shown to improve immune function in elderly humans: a landmark trial showed that low-dose everolimus for six weeks before influenza vaccination enhanced antibody responses in subjects over 65, presumably by reducing immunosenescence and restoring autophagy in aged immune cells. This suggests that periodic mTOR inhibition β whether pharmacological or through lifestyle β may rejuvenate immune function in aging.
18 slides across 7 modules β see mTOR--presentations for the full slide-by-slide reference with embedded images.
| Module | Slides | Key topics |
|---|---|---|
| 01 Introduction | 38 | Rapamycin & immunengram |
| 03 Neuroendocrinology | 225 | Fasting as hormetic mTOR reduction |
| 05 Connective Tissue | 121, 122, 123 | Leucine β mTOR in injury rehab |
| 06 Organs I | 173 | Curcumin inhibits Akt/mTOR in IBD |
| 07 Selfish Immune System | 38, 148 | Selfish brain cycling, intermittent living |
| 08 Diagnosis | 41 | Rapamycin in immunogram experiments |
| 10 Nutrition & Movement | 12, 19, 20, 21, 45, 62, 128, 138, 166, 177 | Activation, sensitisation, periodisation, gut-muscle axis, AMPK trade-off |